| Title: |
1-Month Results From a Prospective Experience on CAS Using CGuard Stent System: The IRONGUARD 2 Study |
| Authors: |
Sirignano P.; Stabile E.; Mansour W.; Capoccia L.; Faccenna F.; Intrieri F.; Ferri M.; Sacca S.; Sponza M.; Mortola P.; Ronchey S.; Grillo P.; Chiappa R.; Losa S.; Setacci F.; Pirrelli S.; Taurino M.; Ruffino M. A.; Udini M.; Palombo D.; Ippoliti A.; Montelione N.; Setacci C.; de Donato G.; Ruggeri M.; Speziale F. |
| Contributors: |
Sirignano, P.; Stabile, E.; Mansour, W.; Capoccia, L.; Faccenna, F.; Intrieri, F.; Ferri, M.; Sacca, S.; Sponza, M.; Mortola, P.; Ronchey, S.; Grillo, P.; Chiappa, R.; Losa, S.; Setacci, F.; Pirrelli, S.; Taurino, M.; Ruffino, M. A.; Udini, M.; Palombo, D.; Ippoliti, A.; Montelione, N.; Setacci, C.; de Donato, G.; Ruggeri, M.; Speziale, F. |
| Publication Year: |
2020 |
| Collection: |
Università degli Studi di Siena: USiena air |
| Subject Terms: |
carotid artery disease; carotid artery stenting; stroke |
| Description: |
Objectives: This study sought to evaluate 30-day safety and efficacy of dual-layer mesh-covered carotid stent systems for carotid artery stenting (CAS) in the clinical practice. Background: When compared with carotid endarterectomy, CAS has been associated with a higher rate of post procedural neurologic events; these could be related to plaque's debris prolapsing through stent's mesh. Consequently, the need for increased plaque coverage has resulted in the development of dual-layer mesh-covered carotid stent systems. Methods: From January 2017 to June 2019, a physician-initiated, prospective, multispecialty registry enrolled 733 consecutive patients undergoing CAS using the CGuard embolic prevention system in 20 centers. The primary endpoint was stroke up to 30 days; secondary endpoints were technical and procedural success; external carotid artery occlusion; and in-hospital and 30-day transient ischemic attack (TIA), acute myocardial infarction (AMI), and death rates. Results: Symptoms were present in 131 (17.87%) patients. An embolic protection device was used in 731 (99.72%) patients. Procedural success was 100%, technical success was obtained in all but 1 (99.86%) patient, who died in hospital due to a hemorrhagic stroke. Six TIAs, 2 minor strokes, and 1 AMI occurred during in-hospital stay, and external carotid artery occlusion was evident in 8 (1.09%) patients. Between hospital discharge and 30-day follow-up, 2 TIAs, 1 minor stroke, and 3 AMIs occurred. Therefore, the cumulative stroke rate was 0.54%. Conclusions: This real-world registry suggests that use of CGuard embolic prevention system in clinical practice is safe and associated with a minimal occurrence of adverse neurological events up to 30-day follow-up. |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/32861633; info:eu-repo/semantics/altIdentifier/wos/WOS:000574473900018; volume:13; issue:18; firstpage:2170; lastpage:2177; numberofpages:8; journal:JACC: CARDIOVASCULAR INTERVENTIONS; https://hdl.handle.net/11365/1276055; https://www.sciencedirect.com/science/article/pii/S1936879820311742 |
| DOI: |
10.1016/j.jcin.2020.05.026 |
| Availability: |
https://hdl.handle.net/11365/1276055; https://doi.org/10.1016/j.jcin.2020.05.026; https://www.sciencedirect.com/science/article/pii/S1936879820311742 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| Accession Number: |
edsbas.4186D314 |
| Database: |
BASE |